Sosei gains Japanese rights to BioAlliance's buccal miconazole
This article was originally published in Scrip
Executive Summary
Sosei has paid $3 million up front for Japanese rights to BioAlliance Pharma's adhesive mucobuccal tablet formulation of miconazole, which it will develop and commercialise for oropharyngeal candidiasis in immunocompromised patients.